

Accepted Manuscript

Title: Peripheral modulation of the endocannabinoid system in metabolic disease

Authors: Nirajan Shrestha, James S.M. Cuffe, Dana S. Hutchinson, John P. Headrick, Anthony V. Perkins, Andrew J. McAinch, Deanne H. Hryciw



PII: S1359-6446(17)30415-4
DOI: <https://doi.org/10.1016/j.drudis.2018.01.029>
Reference: DRUDIS 2162

To appear in:

Please cite this article as: Shrestha, Nirajan, Cuffe, James S.M., Hutchinson, Dana S., Headrick, John P., Perkins, Anthony V., McAinch, Andrew J., Hryciw, Deanne H., Peripheral modulation of the endocannabinoid system in metabolic disease. Drug Discovery Today <https://doi.org/10.1016/j.drudis.2018.01.029>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Peripheral modulation of the endocannabinoid system in metabolic disease

Nirajan Shrestha¹, James S.M. Cuffe¹, Dana S. Hutchinson², John P. Headrick¹, Anthony V.

Perkins¹, Andrew J. McAinch^{3,4} and Deanne H. Hryciw^{3,5,*}

¹School of Medical Science, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia

²Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia

³Centre for Chronic Disease, College of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia

⁴Australian Institute of Musculoskeletal Science (AIMSS), College of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia

⁵School of Natural Science, Menzies Health Institute Queensland, Griffith University, Nathan, QLD, Australia

*Corresponding author: Hryciw, D.H. (d.skelly@griffith.edu.au).

Highlights:

- The endocannabinoid system (ECS) is dysregulated in obesity-associated diseases
- CB₁ antagonism is a potential therapeutic target for the treatment of obesity
- CB₁ antagonists have the potential for eliciting severe psychiatric side effects
- Antagonists of CB₁ that do not cross the blood–brain barrier are in development
- Peripherally restricted CB₁ antagonists are novel therapeutic targets for obesity

Teaser: This Keynote review discusses the peripheral modulation of the ECS in liver, adipose tissue, heart, skeletal muscle, gastrointestinal tract, pancreas, kidney and the immuno-inflammatory system.

Download English Version:

<https://daneshyari.com/en/article/8409861>

Download Persian Version:

<https://daneshyari.com/article/8409861>

[Daneshyari.com](https://daneshyari.com)